<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888378</url>
  </required_header>
  <id_info>
    <org_study_id>HY02-002</org_study_id>
    <nct_id>NCT03888378</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled Study of the Efficacy and Safety of HY02 Ointment in Subjects With Inflamed Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hovione Scientia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hovione Scientia Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of two strengths of HY02 Ointment versus Vehicle
      administered twice daily for twelve weeks in subjects with a diagnosis of Inflamed Meibomian
      Gland Dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">January 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Care provider is a designated dosing coordinator who will be unblinded for this study. Both participant and investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Vascular Engorgement in 1% HY02 Ointment compared to vehicle at week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes in Vascular Engorgement at the study eyelid margin are graded on a 5-point scale (0-4) with 0 representing minimal vascular engorgement and 4 representing maximal vascular engorgement. A lower score represents a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Eye Discomfort Visual Analogue Score (VAS) at week 12 in the 1% HY02 Ointment arm compared to vehicle</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Eye discomfort will be evaluated on a subject reported visual analog scale. The scores range from 0 (no discomfort) to 100 (maximal discomfort). Lower score indicate a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Vascular Engorgement in 0.3% HY02 Ointment compared to vehicle at week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Changes in Vascular Engorgement at the study eyelid margin are graded on a 5-point scale (0-4) with 0 representing minimal vascular engorgement and 4 representing maximal vascular engorgement. A lower score represents a better outcome for the subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Eye Discomfort Visual Analogue Score (VAS) at week 12 in the 0.3% HY02 Ointment arm compared to vehicle</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Eye discomfort will be evaluated on a subject reported visual analog scale. The scores range from 0 (no discomfort) to 100 (maximal discomfort). Lower score indicate a better outcome for the subject.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>MGD-Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>0.3% Topical Minocycline Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID, morning and evening to eyelid margin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% Topical Minocycline Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID, morning and evening to eyelid margin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Vehicle Ointment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of Topical Vehicle Ointment. Regimen: Apply BID, morning and evening to eyelid margin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Topical Minocycline Ointment</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment</description>
    <arm_group_label>0.3% Topical Minocycline Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 0.3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Topical Minocycline Ointment</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment</description>
    <arm_group_label>1% Topical Minocycline Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Vehicle Ointment</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment</description>
    <arm_group_label>Topical Vehicle Ointment</arm_group_label>
    <other_name>HY02 Topical Ointment, 0%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At Visit 1, individuals of any gender or any race will be eligible for study
             participation if they:

               1. Have provided written informed consent prior to any study procedures.

               2. Are 18 years of age or above.

               3. Have a clinical diagnosis of moderate to severe MGD and who meet the following
                  criteria, in a qualifying eyelid, at both Visit 1 (Screening) and Visit 2
                  (Randomization) examinations:

                    1. Clinical sign severity score of at least 2 (moderate) on vascular
                       engorgement at the eyelid margin and

                    2. Clinical sign severity score of at least 2 (moderate) on plugging of the
                       meibomian glands.

                    3. Eye Discomfort Symptom score of ≥ 40 using VAS (0-100 point scale)

               4. Meet the following criteria, in a qualifying eye (same eye that qualifies for
                  Inclusion #3), at both the Visit 1 (Screening) and Visit 2 (Randomization)
                  examinations:

                    1. Fluorescein corneal staining (FCS) total score ≥ 3 in the inferior, central,
                       and nasal region combined score (NEI/Industry Workshop sections 1, 4 and 5
                       with 0-9 scale)

                    2. Schirmer score of &gt;7 mm without topical anesthesia

               5. Are willing and able to follow instructions and can be present for the required
                  study visits for the duration of the study.

               6. Have a BCVA, using corrective lenses if necessary, in both eyes of at least +0.7
                  as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) or modified
                  ETDRS.

               7. If female, are non-pregnant, non-lactating and women of childbearing potential
                  (WOCBP) must be using an acceptable method of birth control [e.g., an
                  Intrauterine Contraceptive Device (IUCD) with a failure rate of &lt;1%, hormonal
                  contraceptives, or a barrier method] for the duration of the study. If a female
                  subject is currently abstinent, they must agree to use one of the acceptable
                  methods of birth control before they become sexually active.

        Exclusion Criteria:

        In order for subjects to be eligible at Visit 1 they may not:

          1. Have presence of inflammation and/or active structural change in the iris or anterior
             chamber.

          2. Have lid structural abnormalities such as entropion or ectropion.

          3. In the eyelid that qualifies (based on Inclusion #3), have grade level 4 (Obstructed)
             on Character of Secretion of Meibomian Glands or grade level 4 (No glands are
             expressible) on the Expressibility of Meibomian Glands.

          4. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis,
             anterior blepharitis, etc.) not related to MGD.

          5. Subjects who have FCS total score = 15 or a score = 3, in either eye, in the superior
             region NEI/Industry Workshop scale or subjects who have FCS with diffuse confluent
             staining, filaments or frank epithelial defects.

          6. Have suspected ocular fungal, viral or bacterial infection.

          7. Have had penetrating intraocular surgery in the past 90 days or require penetrating
             intraocular surgery during the study.

          8. Have had ocular surface surgery within 12 months of Visit 1 (e.g., LASIK, refractive,
             pterygium removal).

          9. Subjects who within the past 90 days have had cauterization of the punctum or changes
             to the status (insertion or removal) of punctal plug(s) before the Screening Visit.

         10. Have used topical ocular or oral antibiotics within 30 days of the study or expect to
             use during the study.

         11. Have used LipiFlow or hypochlorous acid spray within 30 days of the study or expect to
             use during the study.

         12. If using inhaled or intranasal corticosteroids, unable to maintain a stable dose for
             the duration of the study.

         13. Have ever used isotretinoin.

         14. If using Omega-3 supplements, dose must be stable for 3 months prior to Visit 1 and
             for the duration of the study.

         15. Have used topical cyclosporine within 30 days of the study or during the study.

         16. Have used topical lifitegrast within 30 days of the study or during the study.

         17. Have used systemic corticosteroids within 30 days prior to study entry or during study
             participation.

         18. Have used topical ocular corticosteroids or ocular non-steroidal anti-inflammatory
             drugs (NSAIDs) within 30 days prior to study entry and during study participation.

         19. Have used topical ocular antihistamine and/or mast cell stabilizers within 30 days
             prior to study entry or during study participation.

         20. Are unable or unwilling to discontinue using any preserved or unpreserved topical
             ocular medications (including artificial tears) upon Screening and for the duration of
             the study.

         21. Are unwilling to discontinue use of contact lenses during the study.

         22. Are unwilling to discontinue use of cosmetic makeup applied to the eyelids or eye
             lashes at the Screening Visit and during the study. If makeup was used, it should be
             removed at least 12 hours prior to Visit 1.

         23. Have a known hypersensitivity to minocycline, any other tetracycline antibiotic, or to
             any of the other ingredients in the investigational product.

         24. Are unable or unwilling to withhold the use of eyelid scrubs or use of mechanical
             therapy during the study.

         25. Have been diagnosed with glaucoma or are currently using any glaucoma medication.

         26. Have a history of herpetic keratitis.

         27. Have a concomitant ocular pathology other than condition under study assessed as
             potentially confounding by the investigator.

         28. Have a serious systemic disease or uncontrolled medical condition that in the judgment
             of the investigator could confound study assessments or limit compliance.

         29. Have been exposed to any investigational drug or investigational device within the
             preceding 30 days.

         30. Are an employee of the site that is directly involved in the management,
             administration, or support of this study or be an immediate family member of the same.

         31. Have trigger factors including conjunctivochalasis, allergic conjunctivitis, contact
             lens intolerance, trichiasis, epithelial basement membrane dystrophy, infectious
             keratitis or conjunctivitis.

         32. Have a documented history of ocular allergies, which, in the judgment of the
             investigator, are likely to have an acute increase in severity due to the expected
             timing of the exposure to the allergen to which the subject is sensitive. Subjects
             sensitive to seasonal allergens that are not expected to be present during the study
             are permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Magrath, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hovione Scientia Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical site - 4</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 16</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 12</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 13</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site 10</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 15</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 18</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 6</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 20</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 19</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 3</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 9</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 7</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 5</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 11</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 2</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 14</name>
      <address>
        <city>Cedar Park</city>
        <state>Texas</state>
        <zip>78613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 1</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 8</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <zip>77573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical site - 17</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minocycline Topical</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>MGD</keyword>
  <keyword>Meibomian Gland Disorder</keyword>
  <keyword>Anti-Bacterial Agent</keyword>
  <keyword>Anti-imflammatory Agent</keyword>
  <keyword>Minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pathologic Processes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

